Cell and Gene Therapy Resources

More results…

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
page
acf-ui-options-page
omapi
acf-taxonomy
acf-post-type
pha_member
lgx_lsp_shortcodes
speaker
e-book
Podcast

Must-See Sessions at Advanced Therapies Week 2025: Ry Leahy, Head of Content, Phacilitate

Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
Asia
Podcast

ATW Speaker Patrick M Gailliot Previews Event and Discusses His Role in Autologous Cell and Gene Therapies

We caught up with Patrick M Gailliot, Sr. Director, Patient Operations at Abeona Therapeutics, to talk to him about why his work gives him so much joy, preview his session at Advanced Therapies Week in Dallas, and explain the value he gets from the event.
Podcast

Cell and Gene Therapy Investment Tracker: The Latest Deals in 2024

Welcome to Phacilitate’s investment tracker where we’ll be looking at the latest deals in the cell and gene therapy industry. We’ll update the cell and gene investment deals weekly.  
Podcast

Texas Cell and Gene Manufacturing Landscape

Ahead of Advanced Therapies Week 2025 in Dallas, we take a look at the Texas cell and gene manufacturing landscape.
Podcast

Going Under the Hood of Singapore’s Cell Therapy Advanced Manufacturing Program

Cell and gene therapies are set to revolutionize the future of medicine, but one of the major hurdles is the production of good quality cells cost-effectively and at scale
Asia
Podcast

Full Agenda Released for Advanced Therapies Week 2025 in Dallas

Phacilitate Unveils Full Agenda for Advanced Therapies Week 2025, Bringing Together Leaders to Shape the Future of Healthcare

Watch Our Latest Webinar On-Demand

Upcoming Event

Up Next: Unlock the Potential of Regulatory T Cells in Cell Therapy Manufacturing 

Watch this on-demand webinar to find out about isolating ultra- rare cell populations at high purity using the CGX10 Cell Isolation System with Sony.
Watch On Demand
Our eBooks and Infographics
At Advanced Therapies Week 2024, the Association for the Advancement of Blood & Biotherapies (AABB) invited industry leaders to convene for a roundtable to discuss ‘The Need for Well-Qualified Personnel.’
This Case Study demonstrates the necessity of exploring alternative manufacturing methods to address production obstacles that may arise in the supply chain for cell and gene therapy products due to their distinctive availability challenges.
Exploring downstream processes with class-defining solutions for bioproduction workflows.
This case study demonstrates how small-volume manufacturers or biotech companies have the option to use high-precision, temperature-controlled automation for aseptic gene therapy production in single-use bags.
As manufacturing pipelines scale in line with increased demand for advanced therapies, there is further demand for digital solutions to support complex manufacturing process development.
Pioneering the future: a compendium of the top Phase I biotech companies at the forefront of innovation within advanced therapies.
This Case study demonstrates the importance of the cell processing and cell culture workflow steps required to improve and develop cell therapies whilst meeting regulatory compliance, increasing speed and reducing costs. 
This Case Study demonstrates how the pressures of CDMOs to support their clients can be intense. GeminiBio discusses the importance of the ability of CDMOs to manage their processes whilst accommodating to their client’s needs as well as other factors that may affect the their ability to demonstrate flexibility.
For this article, PROGEN’s Dana Holzinger (Head of Product Management), Katja Betts (CEO) and Caroline Odenwald (Head of Marketing) discuss the need to anticipate change when developing AAV gene therapy to reduce uncertainty whilst still supporting innovation and resilience as the path to success can be complex with many challenges.
Exploring digital solutions for cell and gene therapy manufacturing: a Pharma 4.0 perspective.